ULTANE® (sevoflurane) studies have demonstrated rapid recovery and emergence results1,2


Recovery and Emergence

Adult patients administered ULTANE showed shorter times (statistically significant) to recovery (extubation, response to command, and orientation) than patients who received isoflurane or propofol1,3,4


View the science behind the claims on PubMed 

Safety Considerations1

Sevoflurane can cause malignant hyperthermia. Postmarketing reports of malignant hyperthermia, some of which have been fatal, have occurred. ULTANE should not be used in patients with known sensitivity to sevoflurane or to other halogenated agents, or in patients with known or suspected susceptibility to malignant hyperthermia.

Adverse events reported by ≥5% of the surgical patients receiving ULTANE in clinical trials during maintenance and emergence included shivering, hypotension, bradycardia, somnolence, agitation, nausea, vomiting, and increased cough.